2.45
-0.11(-4.30%)
Currency In USD
| Previous Close | 2.56 |
| Open | 2.59 |
| Day High | 2.79 |
| Day Low | 2.45 |
| 52-Week High | 32.5 |
| 52-Week Low | 2.45 |
| Volume | 40,305 |
| Average Volume | 24,871 |
| Market Cap | 2.35M |
| PE | -0.16 |
| EPS | -15 |
| Moving Average 50 Days | 5.72 |
| Moving Average 200 Days | 9.4 |
| Change | -0.11 |
If you invested $1000 in Adial Pharmaceuticals, Inc. (ADIL) since IPO date, it would be worth $24.2 as of February 21, 2026 at a share price of $2.45. Whereas If you bought $1000 worth of Adial Pharmaceuticals, Inc. (ADIL) shares 5 years ago, it would be worth $35 as of February 21, 2026 at a share price of $2.45.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 17, 2026 2:00 PM GMT
GLEN ALLEN, Va., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and r
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
GlobeNewswire Inc.
Feb 04, 2026 2:35 PM GMT
GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and r
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
GlobeNewswire Inc.
Feb 03, 2026 9:05 PM GMT
Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026GLEN ALLEN, Va., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused